<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272414</url>
  </required_header>
  <id_info>
    <org_study_id>10-0261-A</org_study_id>
    <nct_id>NCT01272414</nct_id>
  </id_info>
  <brief_title>Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Toronto</source>
  <brief_summary>
    <textblock>
      Currently there are few therapeutic options for the treatment of lid retraction secondary to
      thyroid orbitopathy (TO) during the active stages of the disease. BoTox injection is capable
      of creating a ptosis, that in the setting of TO can return the upper lid to a more
      physiologic position, thus improving cosmesis, corneal lubrication and potentially quiescent
      stage lid position. This investigation aims to examine the properties of this relationship.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of funding
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in upper lid retraction (in mm)</measure>
    <time_frame>4 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective improvement in lid retraction related dry eye symptoms</measure>
    <time_frame>4 months</time_frame>
    <description>ocular surface disease index score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective improvement in lid retraction related cosmesis</measure>
    <time_frame>4 months</time_frame>
    <description>Graves Orbitopathy quality of life score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Graves Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>BoTox Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive BoTox injection to levator complex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline injection to levator complex</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>2-12 units in weekly 2u doses to effect</description>
    <arm_group_label>BoTox Treatment</arm_group_label>
    <other_name>BoTox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline injection</intervention_name>
    <description>Injection of 0.4cc 0.9% normal saline</description>
    <arm_group_label>Saline injection</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active stage thyroid orbitopathy, as determined by symptom onset of under 6 months.

          -  Upper eyelid retraction of 1mm or greater.

          -  Complaining of either significant ocular symptoms (despite appropriate use of ocular
             lubricants), or bothered by the cosmetic deformity associated with the eyelid
             retraction.

        Exclusion Criteria:

          -  Less than 18 years of age

          -  Age over 65 years

          -  Pregnant or nursing

          -  Known peripheral neuropathy or neuromuscular junction disorder

          -  Demonstrated allergy to BoTox

          -  Current infection over the injection site

          -  Are currently taking any of the following medications: aminoglycosides, penicillamine,
             quinine, and calcium channel blockers.

          -  Previous or concurrent prednisone therapy

          -  Undergone previous upper eyelid surgery

          -  Severe vision threatening TO
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel B Rootman, MSc MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nancy Tucker, MD FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dr Nancy Tucker, MD FRCSC</name_title>
    <organization>University of Toronto</organization>
  </responsible_party>
  <keyword>Eyelid retraction</keyword>
  <keyword>Botulinum Toxins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

